| HOME >> BIOLOGY >> TECHNOLOGY |
Current portion of long term debt 4,000,000 -
Total current liabilities 8,996,550 14,194,226
Warrants to purchase Series C convertible
redeemable preferred stock - 2,423,370
Other long-term liabilities 374,040 -
Long term debt 16,668,458 -
Total liabilities 26,039,048 16,617,596
Minority interest -- Series C convertible
redeemable preferred stock of PharmAthene
Canada, Inc. $0.001 par value; unlimited
shares authorized; 2,591,654 issued and
outstanding; liquidation preference in the
aggregate of $2,719,178 - 2,545,785
Series A convertible redeemable preferred
stock; $0.001 par value; 16,442,000 shares
authorized, issued and outstanding; liquidation
preference in the aggregate of $19,355,388 - 19,130,915
Series B convertible redeemable preferred
stock; $0.001 par value; 65,768,001 shares
authorized; 30,448,147 issued and outstanding;
liquidation preference in the aggregate of
$33,010,797 - 31,780,064
Series C convertible redeemable preferred
stock; $0.001 par value; 22,799,574 shares
authorized; 14,946,479 issued and outstanding;
liquidation preference in the aggregate of
$15,681,930 - 14,480,946
Stockholders' deficit:
Common stock, $0.0001 par value;
100,000,000 shares authorized; 22,138,723
and 22,087,121 shares issued and
outstanding; respectively at December 31,
2007 and 621,281 shares issued and
outstanding at Decembe
'/>"/>
| SOURCE PharmAthene, Inc. Copyright©2008 PR Newswire. All rights reserved |